KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Sales and Divestitures: 2011-2017

Historic Gains from Sales and Divestitures for Biomarin Pharmaceutical (BMRN) over the last 7 years, with Dec 2017 value amounting to $837,926.

  • Biomarin Pharmaceutical's Gains from Sales and Divestitures rose 11.54% to $837,926 in Q4 2017 from the same period last year, while for Dec 2017 it was $837,926, marking a year-over-year increase of 11.54%. This contributed to the annual value of $837,926 for FY2017, which is 11.54% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Gains from Sales and Divestitures stood at $837,926 for FY2017, which was up 11.54% from $751,203 recorded in FY2016.
  • Biomarin Pharmaceutical's Gains from Sales and Divestitures' 5-year high stood at $837,926 during FY2017, with a 5-year trough of $300,968 in FY2013.
  • For the 3-year period, Biomarin Pharmaceutical's Gains from Sales and Divestitures averaged around $692,810, with its median value being $751,203 (2016).
  • Data for Biomarin Pharmaceutical's Gains from Sales and Divestitures shows a peak YoY spiked of 53.53% (in 2016) over the last 5 years.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Gains from Sales and Divestitures stood at $300,968 in 2013, then grew by 27.37% to $383,332 in 2014, then grew by 27.64% to $489,301 in 2015, then spiked by 53.53% to $751,203 in 2016, then rose by 11.54% to $837,926 in 2017.